JP2024506351A5 - - Google Patents

Info

Publication number
JP2024506351A5
JP2024506351A5 JP2023548623A JP2023548623A JP2024506351A5 JP 2024506351 A5 JP2024506351 A5 JP 2024506351A5 JP 2023548623 A JP2023548623 A JP 2023548623A JP 2023548623 A JP2023548623 A JP 2023548623A JP 2024506351 A5 JP2024506351 A5 JP 2024506351A5
Authority
JP
Japan
Prior art keywords
nucleic acid
modified oligonucleotide
alkyl
alkenyl
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016015 external-priority patent/WO2022173976A1/en
Publication of JP2024506351A publication Critical patent/JP2024506351A/ja
Publication of JP2024506351A5 publication Critical patent/JP2024506351A5/ja
Pending legal-status Critical Current

Links

JP2023548623A 2021-02-11 2022-02-10 Plnの発現を低減するための化合物及び方法 Pending JP2024506351A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148579P 2021-02-11 2021-02-11
US63/148,579 2021-02-11
PCT/US2022/016015 WO2022173976A1 (en) 2021-02-11 2022-02-10 Compounds and methods for reducing pln expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026077147A Division JP2026129871A (ja) 2021-02-11 2026-05-01 Plnの発現を低減するための化合物及び方法

Publications (2)

Publication Number Publication Date
JP2024506351A JP2024506351A (ja) 2024-02-13
JP2024506351A5 true JP2024506351A5 (cg-RX-API-DMAC7.html) 2025-02-13

Family

ID=82837329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548623A Pending JP2024506351A (ja) 2021-02-11 2022-02-10 Plnの発現を低減するための化合物及び方法

Country Status (11)

Country Link
US (1) US20240191232A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506351A (cg-RX-API-DMAC7.html)
KR (1) KR20230145133A (cg-RX-API-DMAC7.html)
CN (1) CN117597442A (cg-RX-API-DMAC7.html)
AU (1) AU2022219976A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210172A1 (cg-RX-API-DMAC7.html)
IL (1) IL304775A (cg-RX-API-DMAC7.html)
MX (1) MX2023009429A (cg-RX-API-DMAC7.html)
WO (1) WO2022173976A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260021596A (ko) 2023-04-05 2026-02-13 아이오니스 파마수티컬즈, 인코포레이티드 Pln 발현을 감소시키는 화합물 및 방법
AU2024308906A1 (en) 2023-06-30 2026-02-05 Atrium Therapeutics, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
TW202528539A (zh) * 2023-09-20 2025-07-16 日商第一三共股份有限公司 抑制受磷蛋白之表現的siRNA
CN119242629B (zh) * 2024-08-01 2025-08-01 北京尧景基因技术有限公司 抑制PLN基因表达的siRNA及其缀合物和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711100A (en) * 1998-11-02 2000-05-22 Regents Of The University Of California, The A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
EP1212416A2 (en) * 1999-08-31 2002-06-12 Ribozyme Pharmaceuticals, Inc. Nucleic acid based modulators of gene expression
US20030050259A1 (en) * 1999-12-06 2003-03-13 Lawrence Blatt Method and reagent for the treatment of cardiac disease
AU2005323437B2 (en) * 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
US7491813B2 (en) * 2005-12-07 2009-02-17 Monsanto Technology Llc Promoter polynucleotides identified from Zea mays for use in plants
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US8207138B2 (en) * 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
EP3169776B1 (en) * 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2018154439A1 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders

Similar Documents

Publication Publication Date Title
JP2022068222A (ja) B型肝炎ウイルス感染のためのRNAi薬
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
TWI881004B (zh) 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
JP2022523467A5 (cg-RX-API-DMAC7.html)
TW202609059A (zh) 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法
RS64001B1 (sr) Metode za lečenje infekcije hepatitisom b
JP2025508677A5 (cg-RX-API-DMAC7.html)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2023514336A5 (cg-RX-API-DMAC7.html)
CN111712573B (zh) 针对骨硬化蛋白的适体及其用途
US9809823B2 (en) DNA aptamers for promoting remyelination
JP2024508896A5 (cg-RX-API-DMAC7.html)
TW202305135A (zh) 用於抑制己酮醣激酶(khk)之組合物及方法
JP2022533358A5 (cg-RX-API-DMAC7.html)
JP2024538859A5 (cg-RX-API-DMAC7.html)
JP2024086876A (ja) アシアロ糖タンパク質受容体1の発現を阻害するためのRNAi剤および組成物
WO2022199685A1 (zh) 具有延长的体内半衰期的核酸分子缀合物
JP2024521907A5 (cg-RX-API-DMAC7.html)
WO2025103391A1 (zh) 用于抑制lpa的基因表达的sirna,含其的组合物及其用途
KR102685034B1 (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체
BR112021003609A2 (pt) produtos e composições
EP4527934A1 (en) Gene delivery system based on metal nanoparticle-nucleic acid conjugate
WO2024245424A1 (zh) 一种用于免疫类疾病的双链核苷酸化合物及其应用
CN119585433A (zh) 一种抑制AGT基因表达的RNAi剂及其应用
JP2025504474A5 (cg-RX-API-DMAC7.html)